Jay Luthar, MD, founder of Boston-based Lutanen Health, both medications share the same FDA black box warning about a risk of thyroid tumors
More research needed on RA, PsA, axSpA To view or add a comment, sign in Review of GLP-1 agonist use in rheumatology - with benefits beyond DM, obesity, improved survival, reduced major cardiovascular and renal events
Nausea is most common during dose escalation and typically improves over time
Any other health claim about glutathione (and there are many promising connections) is in its infancy and more studies are needed. Katherine Marengo, LDN, R.D
Dermatology consultation at DermaVue starts at 300
What Fiber Supports GLP-1 Users Naturally